Our newly validated M2 suppression assay based on i) the co-culture of autologous monocyte-derived M2 macrophages and activated CD4+ T cells (or PBMCs) and on ii) the quantitation of IFNg levels as surrogate of T cell activation, is specifically designed to assess new immunotherapeutics for their modulatory activity on the phenotype and function of M2 macrophages.

Candidate compounds can thus be evaluated as single agents or in combinatorial treatments, for their potential to repolarize / switch M2 macrophages and to antagonize M2-mediated T cell suppression.

Learn more about our macrophage assays

 

Leave a Reply

Your email address will not be published.

This field is required.

You may use these <abbr title="HyperText Markup Language">html</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This field is required.

WordPress Lightbox